Showing 8681-8690 of 21420 results for "".
The Impact of Race and Ethnicity on Insulin Regimens
https://reachmd.com/programs/diabetes-discourse/the-impact-of-race-and-ethnicity-on-insulin-regimens/6295/The relationship of insulin regimens to race and ethnicity is a new and growing area of research to better understand and provide clinical care at a personalized level. What are significant differences and approaches to these patients' diabetes management? Join host Dr. Steven Edelman and his guest,NICE-SUGAR: Blood Glucose Levels in the ICU
https://reachmd.com/programs/diabetes-discourse/nice-sugar-blood-glucose-levels-in-the-icu/4825/Lowering blood sugar levels in critically ill patients is a widely embraced practice. But according to the results of the NICE-SUGAR study, lowering blood glucose levels in ICU patients may not be safe. Join host Dr. Steven Edelman and his guest, Dr. Irl Hirsch, professor of medicine and the DiabeteNavigating Gastrointestinal Impacts of GLP-1 Receptor Agonists
https://reachmd.com/programs/gi-insights/navigating-gastrointestinal-impacts-of-glp-1-receptor-agonists/35943/GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in RocThe Role of Incretins for In-Hospital Management
https://reachmd.com/programs/diabetes-discourse/the-role-of-incretins-for-in-hospital-management/5876/Guidelines that avoid the use of oral antidiabetes agents associated with hypoglycemia and weight gain are becoming increasingly popular in treating patients with diabetes. What are we learning about incretin-based therapies in both the intensive care and emergency medicine departments and perioperaMultiple Choice: Customizing Insulin Therapy
https://reachmd.com/programs/diabetes-discourse/multiple-choice-customizing-insulin-therapy/5287/Multiple choices of insulin therapy have provided a decided advantage to both the healthcare provider and patient living with diabetes. What are the specific benefits of customizing insulin therapy for our patients? Join host Dr. Steven Edelman and his guest, professor of medicine at Oregon HealthPracticing Physicians Speak Out: CME As We Need It - Part One
https://reachmd.com/programs/lifelong-learning/practicing-physicians-speak-out-cme-as-we-need-it-part-one/6032/When CME content is designed and developed, it is based on educational needs assessments. But needs vary across the spectrum of physicians and types of practices they engage in. What kind of CME is most needed? What are the shortcomings of current delivery modes, as well as CME types? How can theyYour COVID-19 Questions Answered
https://reachmd.com/programs/public-health-call/your-covid-19-questions-answered/11329/Are face masks and hand sanitizer effective? Should I cancel my upcoming travel plans? Get answers to these and other FAQs.Rewriting the Calcium Code in ADH1
https://reachmd.com/programs/cme/rewriting-the-calcium-code-in-adh1/54833/Explore CALIBRATE findings and ENDO 2026 updates on mechanism-based therapy and evolving management strategies for autosomal dominant hypocalcemia type 1.Redefining Durability in Wet AMD: Insights from the SOL‑1 Superiority Trial
https://reachmd.com/programs/medical-industry-feature/wet-amd-sol1-superiority-trial-durability/56418/The SOL-1 Phase 3 superiority trial compared the efficacy and safety of the investigational product OTX-TKI (axitinib intravitreal hydrogel) with aflibercept 2 mg. The primary endpoint was proportion of subjects who maintained visual acuity, defined as <15 Early Treatment Diabetic Retinopathy StuEpinephrine Evolution: New Developments in Food Allergy Treatment
https://reachmd.com/programs/frontlines-food-allergies/epinephrine-evolution-new-developments-in-food-allergy-treatment/26316/Here’s how nasal and sublingual epinephrine may help address some of the common challenges associated with the traditional injection type.